These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30123826)

  • 1. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients.
    Engels EA; Jennings LW; Everly MJ; Landgren O; Murata K; Yanik EL; Pfeiffer RM; Onaca N; Klintmalm GB
    Transplant Direct; 2018 Jun; 4(6):e353. PubMed ID: 30123826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.
    Engels EA; Preiksaitis J; Zingone A; Landgren O
    Am J Transplant; 2012 May; 12(5):1268-74. PubMed ID: 22300426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.
    Engels EA; Savoldo B; Pfeiffer RM; Costello R; Zingone A; Heslop HE; Landgren O
    Transplantation; 2013 Feb; 95(3):519-26. PubMed ID: 23222884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.
    Ready E; Chernushkin K; Partovi N; Hussaini T; Luo C; Johnston O; Shapiro RJ
    Can J Kidney Health Dis; 2018; 5():2054358118760831. PubMed ID: 29636980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
    Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders.
    Kaleem Z; Hassan A; Pathan MH; White G
    Arch Pathol Lab Med; 2004 Feb; 128(2):181-6. PubMed ID: 14736286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
    Praghakaran K; Wise B; Chen A; Schwarz K; Colombani P
    J Pediatr Surg; 1999 Jan; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders.
    Borrows R; Scheer A; Cockwell P; Braun F; Anagnostopoulos I; Riess H; Zimmermann H; Trappe RU
    Ann Hematol; 2019 Mar; 98(3):625-632. PubMed ID: 30680506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.
    Quinlan SC; Pfeiffer RM; Morton LM; Engels EA
    Am J Hematol; 2011 Feb; 86(2):206-9. PubMed ID: 21264909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
    Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
    Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys.
    Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB
    Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
    Babel N; Vergopoulos A; Trappe RU; Oertel S; Hammer MH; Karaivanov S; Schneider N; Riess H; Papp-Vary M; Neuhaus R; Gondek LP; Volk HD; Reinke P
    Transplantation; 2007 Aug; 84(3):387-91. PubMed ID: 17700165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.
    Proust A; Rincé P; Creidy R; Lazure T; Joab I; Garçon L; Fabre M; Guettier C; Raphael M
    Am J Pathol; 2011 Oct; 179(4):1630-7. PubMed ID: 21871426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.